Gonadorelin (GnRH), Research Reference

Gonadorelin (also referred to as GnRH, LHRH, luteinising hormone-releasing hormone, or gonadorelin acetate) is a synthetic decapeptide of 10 amino acids with a sequence identical to endogenous gonadotropin-releasing hormone, the hypothalamic hormone that governs the hypothalamic-pituitary-gonadal (HPG) axis.

Gonadorelin was approved by the FDA as Factrel for diagnostic evaluation of pituitary gonadotropin function, and formerly as Lutrepulse, a pulsatile pump delivery system for ovulation induction. Research interest in Gonadorelin within the peptide community has grown substantially following FDA restrictions on compounded hCG, positioning Gonadorelin as an alternative for maintaining HPG axis function alongside testosterone replacement therapy.

Quick Reference

Overview

Gonadorelin is the synthetic form of the endogenous hypothalamic decapeptide that acts as the master regulator of the reproductive hormonal axis. Under normal physiological conditions, the hypothalamus releases GnRH in discrete pulses approximately every 60–120 minutes, driving corresponding pulsatile releases of LH (luteinising hormone) and FSH (follicle-stimulating hormone) from the anterior pituitary.

The pulsatile nature of GnRH signalling is critical to its function. When GnRH receptors on anterior pituitary gonadotroph cells are exposed continuously rather than intermittently, they undergo downregulation, and LH and FSH secretion falls rather than rises. This paradoxical suppression is the basis for the therapeutic use of GnRH agonists (such as leuprolide and buserelin) in hormone-sensitive cancers and conditions where gonadotropin suppression is clinically desired.

In research and clinical contexts relevant to the peptide community, Gonadorelin is used with the opposite goal: to maintain stimulatory LH and FSH output during exogenous testosterone use, by replicating the pulsatile GnRH signal at intervals long enough to allow receptor resensitisation between doses.

Research has investigated Gonadorelin for its potential role in:

• HPG axis maintenance during TRT: Exogenous testosterone suppresses hypothalamic GnRH and pituitary LH and FSH secretion via negative feedback. Research has investigated whether periodic Gonadorelin administration can partially preserve pituitary responsiveness and downstream testicular function during TRT.
• Intratesticular testosterone maintenance: LH drives Leydig cell production of intratesticular testosterone. Anecdotal research accounts describe Gonadorelin administration preserving testicular volume and intratesticular testosterone during exogenous testosterone protocols.
• FSH-dependent spermatogenesis: Unlike hCG, which acts directly at the testicular LH receptor without stimulating FSH, Gonadorelin drives pituitary FSH secretion alongside LH. FSH acts on Sertoli cells and is required for spermatogenesis, making Gonadorelin of interest for fertility preservation during TRT.
• Ovulation induction in hypothalamic amenorrhoea: Medically supervised pulsatile pump delivery of Gonadorelin has been used to restore ovulatory cycles in women with hypothalamic amenorrhoea, where absent or insufficient GnRH pulsatility is the underlying mechanism.
• Spermatogenesis stimulation in hypogonadotropic hypogonadism: Research has investigated pulsatile GnRH therapy for stimulating spermatogenesis in men with GnRH deficiency, including those with idiopathic hypogonadotropic hypogonadism and Kallmann syndrome.

Reported Protocols

The following information represents commonly reported research ranges drawn from anecdotal accounts and published research literature. These are not medical recommendations.

Subcutaneous Protocol in TRT Context

Subcutaneous injection is the administration route reported in virtually all non-clinical Gonadorelin research accounts. Commonly reported doses range from 100 mcg per injection, administered on a twice-weekly or three-times-weekly schedule.

• Commonly reported protocol (twice weekly): 100 mcg subcutaneous injection twice per week, typically timed on the same days as testosterone injections
• Commonly reported protocol (three times weekly): 100 mcg subcutaneous injection three times per week, spacing injections as evenly as possible across the week
• Dosing rationale: The short half-life (2–10 minutes) means that each injection produces a brief pulse of GnRH receptor stimulation, which is cleared rapidly. The interval between doses (2–3 days) is sufficient to allow receptor resensitisation, preserving the stimulatory response.

Pulsatile Pump Delivery (Medically Supervised Research Context)

The physiologically accurate replication of endogenous GnRH pulsatility requires dedicated pulsatile pump delivery. Commonly reported doses in clinical research for hypothalamic amenorrhoea and hypogonadotropic hypogonadism range from 2.5 mcg to 10 mcg per pulse, delivered every 90 minutes via a programmable subcutaneous or intravenous pump. This approach is medically supervised and is distinct from the subcutaneous injection protocols described above.

Reported Effects

The following effects have been reported in research literature and anecdotal accounts. This list reflects the research landscape, not confirmed clinical outcomes in general populations.

LH and FSH Stimulation

The primary pharmacological effect of Gonadorelin at the doses described in research accounts is a transient rise in LH and FSH following each injection. Anecdotal reports describe measurable increases in serum LH and FSH on blood work conducted within 30–60 minutes of injection, returning toward baseline within a few hours given the downstream hormones’ longer half-lives.

Maintenance of Intratesticular Testosterone

Anecdotal research accounts, along with published clinical data on GnRH therapy in hypogonadotropic hypogonadism, report that periodic LH stimulation supports Leydig cell activity and intratesticular testosterone production. In TRT-context research accounts, maintenance of intratesticular testosterone is associated with preservation of testicular volume, which commonly diminishes with exogenous testosterone use alone.

Preservation of Testicular Volume

Testicular atrophy is a commonly reported consequence of exogenous testosterone use, driven by suppression of LH and FSH. Anecdotal research accounts describe Gonadorelin as associated with reduced testicular atrophy during TRT protocols, with some accounts noting partial or full maintenance of testicular volume compared to controls using testosterone without any HPG axis support.

FSH-Driven Spermatogenesis Support

Because Gonadorelin stimulates both LH and FSH, research accounts suggest it may offer an advantage over hCG for individuals for whom fertility preservation during TRT is a concern. FSH acts on Sertoli cells to support spermatogenesis; published pulsatile GnRH research in hypogonadotropic hypogonadism has demonstrated successful sperm production in individuals who initially had no detectable sperm.

Ovulation Induction and Fertility (Female Research Context)

Published research on pulsatile Gonadorelin pump delivery in women with hypothalamic amenorrhoea has reported restoration of ovulatory cycles and successful pregnancies. This application is medically supervised and distinct from the subcutaneous injection protocols described in the TRT research context.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

Gonadorelin is generally reported as well tolerated at the twice-weekly subcutaneous doses described in TRT-context research accounts. The very short half-life limits systemic exposure duration, and the intermittent dosing schedule is designed to avoid the receptor downregulation that occurs with continuous GnRH agonist exposure.

Storage and Handling

Lyophilized Powder (Unreconstituted)

• Refrigerator (2–8 degrees C): Preferred storage condition; commonly reported stable for 12 months or more when kept away from light and moisture
• Room temperature: Reported stable short-term; refrigerator preferred for longer storage
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles
• Light sensitivity: Protect from light; store in an opaque or amber vial

Reconstituted Solution

• Refrigerator (2–8 degrees C): Use within 2–4 weeks of reconstitution. Given Gonadorelin’s short peptide half-life, preparing fresh reconstituted solution is preferable where possible.
• Do not freeze a reconstituted solution
• Bacteriostatic water (BAC water) is the standard diluent for multi-use vials
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Add bacteriostatic water slowly along the inside wall of the vial. Swirl gently, do not shake. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

Why does pulsatile dosing matter with Gonadorelin? Gonadorelin’s mechanism depends on intermittent exposure to GnRH receptors in the anterior pituitary. Continuous or high-frequency stimulation causes receptor downregulation and paradoxical suppression of LH and FSH release. This is the same pharmacological principle exploited by GnRH agonists in hormone-sensitive cancer therapy. At typical twice-weekly or three-times-weekly subcutaneous research doses, the interval between injections is long enough relative to Gonadorelin’s 2–10 minute half-life to preserve stimulatory receptor responsiveness rather than triggering suppression.

How does Gonadorelin compare to hCG in TRT protocols? Both Gonadorelin and human chorionic gonadotropin (hCG) are used in TRT-adjacent research protocols with the goal of maintaining testicular function. hCG acts directly at the testicular LH receptor, bypassing the pituitary entirely. Gonadorelin acts upstream at the pituitary, stimulating the body’s own LH and FSH secretion. Anecdotal research accounts suggest that Gonadorelin may offer an advantage by also maintaining FSH levels, which hCG does not directly stimulate. Compounded Gonadorelin has become more common since the FDA placed restrictions on compounded hCG.

Does Gonadorelin preserve fertility during TRT? Anecdotal research accounts and some clinical reports suggest that Gonadorelin, by maintaining FSH signalling to the testes, may help preserve spermatogenesis during exogenous testosterone use. Fertility outcomes depend on many individual variables and clinical supervision is relevant to anyone for whom fertility preservation is a priority.

Why does frequency matter more than dose for Gonadorelin? Given Gonadorelin’s plasma half-life of 2–10 minutes, the compound is cleared rapidly after each injection. The key variable governing its effect on the pituitary is the pattern of receptor stimulation: intermittent pulses allow receptor resensitisation between doses, maintaining LH and FSH output. Raising the dose without maintaining adequate spacing does not necessarily improve the stimulatory response and may contribute to receptor desensitisation. Commonly reported research protocols therefore prioritise dosing frequency rather than increasing the dose per injection beyond the commonly reported 100 mcg range.

Related Pages

Goals: Testosterone and Hormonal Support · Fertility and Reproductive Health

Also see: Kisspeptin

Comparisons: Gonadorelin vs Triptorelin

References and Further Reading

• Spratt DI, et al. (1987). Pulsatile gonadotropin-releasing hormone treatment of male hypogonadotropic hypogonadism. Annals of Internal Medicine, 107(3), 239–243. PubMed
• Crowley WF Jr, et al. (1985). The physiology of gonadotropin-releasing hormone (GnRH) secretion in men and women. Recent Progress in Hormone Research, 41, 473–531. PubMed
• Filicori M, et al. (2002). The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertility and Sterility, 77(6), 1133–1145. PubMed
• Schopohl J, et al. (1991). Comparison of gonadotropin-releasing hormone and gonadotropin therapy in male patients with idiopathic hypothalamic hypogonadism. Fertility and Sterility, 56(6), 1143–1150. PubMed